GlassScriptPhysician profile
Dana A Bleakney
NPI 1255368502
$11,305.39
in general payments reported to CMS, 2019-2025
51 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $915 · 2021: $1,975 · 2022: $1,348 · 2023: $1,832 · 2024: $1,993 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,821.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,521.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,275.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,091.33 | 2021-2025 | Qulipta, Ubrelvy, Synthroid |
| Abbott Laboratories | $718.57 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $680.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $581.64 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $578.75 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $576.73 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $427.93 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $390.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $366.76 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.99 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Axsome Therapeutics, INC. | $206.77 | 2025 | Auvelity, Symbravo |
| Amgen INC. | $186.93 | 2019-2025 | Evenity, Krystexxa, Repatha |
| Dexcom, INC. | $183.93 | 2021-2024 | Dexcom G6 Transmitter |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Bleakney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.